CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-10 | MOMTAZEE JAMES C Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-10 | Epperly Melissa B, Director | Grant or award | +14,524 | 57,509 | ||
| 2025-09-10 | Epperly Melissa B, Director | Other disposition | −1,661 | $13.77 | $23K | 55,848 |
| 2025-09-10 | Epperly Melissa B, Director | Grant or award · Stock Option (Right to Buy) | +33,726 | 33,726 | ||
| 2025-09-05 | Ramaswamy Vivek 10% owner | Sale | −385,816 | $12.96 | $5.0M | 35,508,359 |
| 2025-09-04 | Ramaswamy Vivek 10% owner | Sale | −194,933 | $12.92 | $2.5M | 35,894,175 |
| 2025-09-03 | Ramaswamy Vivek 10% owner | Sale | −1,195,000 | $12.50 | $14.9M | 36,089,108 |
| 2025-08-28 | Pulik Richard CFO | Shares withheld for taxes | −2,340 | $11.94 | $28K | 393,978 |
| 2025-08-20 | Pulik Richard CFO | Shares withheld for taxes | −1,235 | $11.72 | $14K | 396,318 |
| 2025-08-20 | Venker Eric President & Immunovant CEO | Shares withheld for taxes 10b5-1 | −7,051 | $11.72 | $83K | 1,653,585 |
| 2025-08-20 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +100,000 | $3.85 | $385K | 1,753,585 |
| 2025-08-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −100,000 | $11.72 | $1.2M | 1,653,585 |
| 2025-08-20 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 8,038,897 | ||
| 2025-07-30 | Torti Frank President and Vant Chair | Grant or award | +1,836,547 | 1,836,547 | ||
| 2025-07-30 | Torti Frank President and Vant Chair | Grant or award | +11,900,000 | 13,736,547 | ||
| 2025-07-30 | Venker Eric President & Immunovant CEO | Grant or award | +198,413 | 1,660,636 | ||
| 2025-07-28 | Pulik Richard CFO | Shares withheld for taxes | −1,919 | $11.35 | $22K | 397,553 |
| 2025-07-21 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +100,000 | $3.85 | $385K | 1,562,223 |
| 2025-07-21 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −100,000 | $11.52 | $1.2M | 1,462,223 |
| 2025-07-21 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 8,138,897 |
Page 20 of 29 · 570 trades